Li Xiuyun, Chen Zhaowen, Jiao Jin, Wang Shifu, Wang Yuehua, Wu Weiwei, Yang Huijun, Lou Hongxiang
Department of Natural Product Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Maternal and Child Health Development Research Center, Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.
Expert Rev Anti Infect Ther. 2023 Jan;21(1):91-98. doi: 10.1080/14787210.2022.2153117. Epub 2022 Dec 12.
Antibiotic resistance has become a public health problem to be solved worldwide and metallo-β-lactamase (MBL)-producing bacteria make this problem even more challenging.
The interactions of meropenem (MEM) in combination with avibactam (AVI) in growth inhibition on MBL-producing carbapenem-resistant (CRKP) strains were tested. interactions of MEM+AVI were tested using the microdilution checkerboard assay and time-kill curves. interactions of MEM+AVI were tested using the model.
All strains were multi-drug resistant strains and six of them were proved to produce MBLs. We show that the combination of MEM+AVI generates profound synergistic effects on growth inhibition of all strains, which was better than that of MEM+vaborbactam or imipenem+relebactam. The time-kill curves further confirmed the potent synergistic antibacterial effects of MEM+AVI against MBL-producing CRKP strains. studies were consistent with analysis. Combining MEM with AVI improved survival rates and mean survival days were obviously prolonged compared to the drug alone and the untreated controls.
To our knowledge, this study is the first report of MEM+AVI collaborating against MBL-producing CRKP strains. Our findings showed that the combination of MEM+AVI has the potential for antibiotic drug development to combat MBL-producing pathogens.
抗生素耐药性已成为全球亟待解决的公共卫生问题,产金属β-内酰胺酶(MBL)的细菌使这一问题更具挑战性。
测试了美罗培南(MEM)与阿维巴坦(AVI)联合对产MBL的耐碳青霉烯类肺炎克雷伯菌(CRKP)菌株生长抑制的相互作用。使用微量稀释棋盘法和时间杀菌曲线测试MEM+AVI的相互作用。使用该模型测试MEM+AVI的相互作用。
所有菌株均为多重耐药菌株,其中6株被证实产MBL。我们发现,MEM+AVI联合对所有菌株的生长抑制产生了显著的协同作用,优于MEM+伏巴拉坦或亚胺培南+雷利巴坦。时间杀菌曲线进一步证实了MEM+AVI对产MBL的CRKP菌株具有强大的协同抗菌作用。研究结果与分析一致。与单独用药和未治疗的对照组相比,联合使用MEM和AVI提高了存活率,平均存活天数明显延长。
据我们所知,本研究是关于MEM+AVI联合对抗产MBL的CRKP菌株的首次报道。我们的研究结果表明,MEM+AVI联合有潜力用于开发对抗产MBL病原体的抗生素药物。